The interaction between the cardiac and renal systems is important in determining blood pressure and blood volume, both of which play a role in the vasomotor system and fluid balance. Cardiorenal syndrome (CRS) occurs as a result of a disparity in correlation between the two. In veterinary medicine, cardiovascular-renal axis disorder (CvRD) lacks pathologically and etiologically specific data, but shares common pathophysiological patterns with CRS and CvRD in humans.
CvRD is structural or functional damage caused by diseases of the heart or kidneys, or toxins or drugs, resulting in the disruption of normal interactions between these organs and the destruction of one or both organs. The aim of this study is to compare the long-term changes in various indicators, including hypertension, proteinuria and echocardiographic parameters, before and after administration of telmisartan in cats with CvRD. This study found a clear gradual decrease in Urine protein to creatinine (UP/C) ratio and left atrium (LA) diameter in cats with CvRD, after administration of telmisartan. UP/C ratio (p<0.001) was found to decrease significantly over time, after administration of telmisartan. UP/C ratio before telmisartan administration was 0.39 ± 0.255 (Day 0) and 0.29 ± 0.056 on day 30 (Day 30), 0.28 ± 0.040 on day 60 (Day 60), and 0.20 ± 0.128 on day 90 (Day 90) after administration, respectively. LA diameter before telmisartan administration was 17.9 mm ± 1.6 before telmisartan administration (Day 0) and 17.4 mm ± 1.8 on day 30 (Day 30), 16.1 mm ± 1.6 on day 60 (Day 60), and 15.7 mm ± 1.7 on day 90 (Day 90) after administration, respectively. Oral administration of telmisartan to cats with CvRD is effective in improving proteinuria and LA diameter, which is a positive aspect of long-term survival in cats with CvRD.
The number of cats requiring treatment for hypertrophic cardiomyopathy (HCM) and arterial thromboembolism (ATE) continues to increase, and the knowledge regarding its management is constantly evolving. The pathological lesions of HCM include hypertrophy of the left ventricle, which causes abnormalities in the relaxation function of the heart. This phenomenon increases the stiffness of the ventricular muscle, thereby reducing the ability of the left ventricle to fill with blood during diastole. This is accompanied by an increase in ventricular filling pressure and left atrial pressure. HCM in cats is characterized by concentric hypertrophy and atrial enlargement. Hypertrophic obstructive cardiomyopathy (HOCM) also involves a narrowed left ventricular outflow tract, and in humans, it is generally perceived to be a more serious disease. However, unlike in humans, HCM and HOCM in cats do not result in significantly different survival times. Heart murmurs, gallop rhythms, arrhythmias, cardiac hypertrophy, congestive heart failure (CHF), ATE, and cardiac sudden death (CSD) have all been associated with HCM. Although the presence of a heart murmur is a characteristic feature of heart disease, it may be a functional one, which is defined as “dynamic right ventricular outflow track obstruction” (DRVOTO) in cats. Therefore, it is difficult to evaluate the presence of HCM based on the existence of a heart murmur alone. ATE typically affects one or both hind limbs, resulting in acute paralysis and severe pain, consistent with lower motor neuron disease. The clot, which is formed in the left atrium of the heart, travels to an artery and becomes an ATE, which then blocks the blood flow and impairs circulation, causing infarction. Therefore, ATE in cats is a serious condition. This review describes the results of the latest research on HCM and ATE, the most common heart conditions in cats.
An 8-year-old castrated male Maltese dog (patient) was referred to our institute with refractory canine babesiosis. The patient had previously responded to conventional treatment with atovaquone and azithromycin; however, anemia had recurred at six weeks after treatment withdrawal. No effect was observed on the administration of the same medication along with diminazene aceturate. On blood analysis, mild anemia was identified, with the absolute reticulocyte count indicating a markedly regenerative state. On Diff-Quik-stained peripheral blood film examination, the parasitic protozoan Babesia gibsoni was observed, and based on further laboratory examinations, a relapse of babesiosis was confirmed. Based on a previous study of drug-resistant variants of B. gibsoni and therapeutic trials, the treatment was then changed to a combination therapy of clindamycin, doxycycline, and metronidazole. Subsequently, the patient’s condition improved rapidly — B. gibsoni was not detected in the blood film and the PCR analysis for it was negative. This treatment was discontinued at six weeks after treatment initiation; however, at seven weeks after the treatment withdrawal, another relapse of babesiosis was confirmed and treatment was restarted with the same protocol. This treatment was effective again and lasted for 12 weeks. However, anemia recurred again at five weeks after withdrawal of the previous treatment and was corrected by restarting the same treatment protocol. This third treatment continued for 24 weeks and was finally stopped at the request of the client. The patient has reportedly been doing well with no manifestation of clinical signs and symptoms. This case report demonstrates that the clindamycin- doxycycline-metronidazole combination therapy against atovaquone and azithromycin-resistant B. gibsoni may be effective in improving the clinical manifestation of symptoms of canine babesiosis and this therapy may be an alternative treatment strategy.
This study compares the differences in the gastrointestinal transit time between the conventional capsule endoscope and a minimized capsule endoscope model in normal dogs to verify whether the minimization of capsule endoscope can help relief retention in the gastrointestinal tract, especially in the pyloric passage. Three male beagles were used as the experimental group for which the minimized capsule endoscope model was orally administered and the control group consisted of three beagle dogs for which the conventional capsule endoscope was orally administered. Nine experiments were conducted with three experiments for each dog in each group. The results showed a significant difference in the gastric transit time (GTT) by the minimization of the capsule endoscope between the two groups (control group: 123.3 ± 80 min, experimental group: 63.3 ± 40.9 min, p=0.019). In contrast, the difference in the small bowel transit time (SBTT) by the minimization of the capsule endoscope between the two groups (control group: 86.6 ± 58.9 min, experimental group: 80 ± 33.5 min, p=0.863) was not significant. In this study, the capsule endoscopes reached the large intestine without retention in the small intestine in all subjects. The significant difference in the GTT between the control group using the conventional capsule endoscope and the experimental group using the minimized capsule endoscope model suggests that the smaller size of the capsule endoscope is helpful in resolving retention in the gastrointestinal tract, thus shorting the GTT.
Angiotensin receptor blockers, such as telmisartan, are considered effective in the treatment of hypertension and proteinuria due to chronic kidney disease (CKD) in cats. It selectively blocks the AT1 receptor and does not affect the AT2 receptor, thus effectively blocking the activity of the renin angiotensin aldosterone system. This study aims to compare over time the changes in various indicators, including systemic hypertension and proteinuria, before and after the administration of telmisartan in cats with CKD. Decrease in blood pressure (BP) (p<0.001) and urine protein to creatinine (UP/C) ratio (p<0.001) were found to be statistically significant over time after the administration of telmisartan. BP and the UP/C ratio were 160 ± 22.2 and 0.50 ± 0.647 before telmisartan administration (Day 0), 150 ± 21.0 and 0.27 ± 0.487 on the 30th day (Day 30), 150 ± 17.0 and 0.25 ± 0.376 on the 60th day (Day 60), and 140 ± 17.8 and 0.15 ± 0.233 on the 90th day (Day 90) after administration, respectively. BP and UP/C were statistically significantly lower in cats with CKD over time at each time point from Day 0 to Day 90 at 30 day intervals. Especially after 90 days of telmisartan administration, the improvement of BP and UP/C were estimated to be about 20 mmHg and 0.35, respectively. In conclusion, the oral administration of telmisartan to cats with CKD is effective in improving BP and proteinuria, which has a positive effect on long-term survival in cats with CKD.
Echocardiography is one of the most useful diagnostic techniques for differentiating heart disease as well as mitral valve lesion. Forty client-owned small breed dogs (weight, 2.3−13.2 kg) aged between 8−17 years with myxomatous mitral valve degeneration (MMVD) were included in the present study. The diagnosis of MMVD in dogs was made based on the clinical signs, chest radiography data, and echocardiographic findings. Echocardiographic examinations were conducted in accordance with recommended standards for dogs. M-mode, Doppler, and 2D echocardiography were performed in left and right lateral recumbency. 2D echocardiography was used to measure LA and Ao diameter from 2D short axis at the level of the aortic valve. In the comparison of conventional echocardiography indices in dogs with different stages of heart failure with MMVD, significant differences were observed in E/A ratio (p=0.005), EDV (p<0.001), EDVI (p<0.001), E-peak velocity (p= 0.001), ESV (p=0.028), ESVI (p=0.004), LA (p<0.001), LA/Ao Ratio (p<0.001), LVIDd (p<0.001), LVIDd/Ao Ratio (p<0.001), LVIDs (p=0.036), LVIDs/Ao Ratio (p=0.002), and MR Velocity (p=0.026). In addition, distinct correlations were found in EDV (r=0.712), LA/Ao ration (r=0.830), LVIDd (r=0.724), and LVIDd/Ao ratio (r=0.759).
This study found that known conventional echocardiographic indices, including EDV, LA/Ao ratio, LVIDd dimension, and LVIDd/Ao ratio correlated with the severity of MMVD in point of significant differences and distinct correlations.